AdjuvanT dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

Medical Oncology

Volumn 23, Issue 4, 2006, Pages 479-488

  Fountzilas, George ^a   Pectasides, Dimitrios ^b   Christodoulou, Christos ^c   Timotheadou, Eleni ^a   Economopoulos, Theofanis ^b   Papakostas, Pavlos ^d   Papadimitriou, Christos ^e   Gogas, Helen ^e   Efstratiou, Ioannis ^a   Skarlos, Dimosthenis ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anthracyclines; Breast cancer; Chemotherapy; Docetaxel

Indexed keywords

ANTIBIOTIC AGENT; AROMATASE INHIBITOR; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; METHOTREXATE; ONDANSETRON; PACLITAXEL; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LYMPHATIC SYSTEM INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT SAFETY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT INFECTION; SEPTICEMIA; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; TAXOIDS;

EID: 33846960804     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:4:479     Document Type: Article

References (20)

1. Norton L. Theoretical concepts and emerging role of taxanes in adjuvant therapy. The Oncologist 2001; 6: 30-35.
2. Henderson IC, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
3. Manounas EP, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
4. Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
5. Fountzilas G, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16(11): 1762-1771.
6. Martin M, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
7. Sparano JA, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. (Abstr 48) 28th Annual San Antonio Breast Cancer Symposium 2005. Breast Cancer Res Treat 2005; 94 (Suppl 1).
8. Chan S, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
9. Jones SE, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 20: 5542-5551.
10. Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-2168.
11. Briasoulis E, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10: 701-706.
12. Burstein HJ, et al. Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 2000; 18: 1212-1219.
13. Stemmler J, et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 2005; 68: 71-78.
14. Tabernero J, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15: 1358-1365.
15. Goldhirsch A, et al. meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
16. Di Leo A, et al. A feasibility study evaluating docetaxelbased sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000; 11: 169-175.
17. Fumoleau P, et al. Adjuvant dose-dense (3 FEC 100 followed 3 docetaxel every 2 weeks) regimen is not feasible. Results of the FNCLCC-PACS 06 Study. (Abstr 2071) 28th Annual San Antonio Breast Cancer Symposium 2005. Breast Cancer Res Treat 2005; 94(Suppl 1): S108.
18. Miller KD, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-3037.
19. Miller KD, et al. Randomized phase II trial of the antiangiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005; 89: 187-197.
20. Dang CT, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004; 10: 5754-5761.